KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Depreciation & Amortization (CF) (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Depreciation & Amortization (CF) data on record, last reported at $55.7 million in Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 19.78% year-over-year to $55.7 million; the TTM value through Dec 2025 reached $209.8 million, up 1.25%, while the annual FY2025 figure was $209.8 million, 1.25% up from the prior year.
  • Depreciation & Amortization (CF) reached $55.7 million in Q4 2025 per VRTX's latest filing, up from $54.0 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $59.0 million in Q4 2023 and bottomed at $28.8 million in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $43.6 million, with a median of $41.8 million recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): soared 53.65% in 2023, then dropped 21.19% in 2024.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $33.8 million in 2021, then grew by 13.61% to $38.4 million in 2022, then skyrocketed by 53.65% to $59.0 million in 2023, then decreased by 21.19% to $46.5 million in 2024, then rose by 19.78% to $55.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $55.7 million in Q4 2025, $54.0 million in Q3 2025, and $51.7 million in Q2 2025.